

Performance in Delivering

1 January 2016 - 31 December 2016

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
15/WM/0050	172460	Efficacy and safety of ingenol mebutate gel 0.015% compared to diclofenacsodium gel 3% in subjects with actinic keratosis on the face or scalp	Number Agreed	8	8	Date Agreed	30/11/2015	8	29/01/2016	8	Recruitment Finished	
15/SC/0443	173722	OPTIMISE ? Long term clear skin maintenance treatment optimisation in patients with moderate to severe chronic plaque psoriasis: A randomised, multi-centre, open-label with blinded-assessment, comparative, 52 week study to evaluate the efficacy, saf	Number Agreed	1	1	Date Agreed	31/03/2016	2	29/01/2016	2	Recruitment Finished	Fast setup recognised by sponsor
15/NI/0169	184948	The impact of severe hypoglycaemic events requiring interventions in patients with type 1 diabetes patients treated insulin therapy	Number Agreed	5	5	Date Agreed	29/01/2016	8	17/02/2016	12	Recruitment Finished	Over recruited
14/WM/0027	144610	THEMIS - A multi national randomised double blind placebo-controlled trial to evaluate the effect of Ticagrelor 90mg daily on the incidence of cardiovascular death, myocardial infarction or stroke in patients with type 2 diabetes.	Number Agreed	20	20	Date Agreed	14/09/2015	6	10/05/2016	10	Recruitment Finished	Care pathway changed mid study hence did not achieve recruitment target
13/EE/0339	122902	CCRN 2162 (Cardiovascular outcomes anti-coagulation strategies)	Number Agreed	30	30	Date Agreed	30/09/2015	45	09/05/2016	53	Recruitment Finished	Over recruited
12/SC/0139	98125	A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAS	Number Agreed	3	3	Not Available / Not Agreed		3	25/02/2016	3	Recruitment Finished	
13/SC/0054	121560	CCRN 1070 (Stroke AF)	Number Agreed	20	20	Date Agreed	31/12/2017	9	24/08/2016	9	Recruitment Finished	Recruitment closed early
15/NW/0626	184626	DIAB 4826 - A Phase 3, Randomized, Double-blind, Placebocontrolled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes	Number Agreed	6	6	Date Agreed	31/03/2017	11	19/08/2016	11	Recruitment Finished	Over recruited - top recruiter in the UK
15/EE/0464	183877	CRIT 4440 - A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LIPC-501 in Patients with Catecholamine-Resistant Hypotension (CRH)	Number Agreed	1	1	Date Agreed	30/06/2016	1	01/12/2016	1	Recruitment Finished	